<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Palivizumab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Palivizumab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Palivizumab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="12672" href="/d/html/12672.html" rel="external">see "Palivizumab: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F205781"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Synagis</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867821"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Synagis</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F205800"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Monoclonal Antibody</li></ul></div>
<div class="block dop drugH1Div" id="F205792"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12672" href="/d/html/12672.html" rel="external">see "Palivizumab: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Palivizumab prophylaxis is not recommended for all patients; the AAP makes recommendations regarding who should be considered for receipt of palivizumab, which are described in detail in "Use" section.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="384fe0c9-97ea-45df-af00-78cc08bbdeb4">Respiratory syncytial virus, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Respiratory syncytial virus (RSV), prevention:</b> Infants and Children &lt;24 months: IM: 15 mg/kg once monthly throughout RSV season, with the first dose administered prior to commencement of RSV season; if hospitalized at the start of RSV season, palivizumab should be given 48 to 72 hours before discharge or promptly after discharge (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25070315']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25070315'])">Ref</a></span>). During a typical RSV season, up to 5 monthly doses are recommended. RSV seasonality was altered following the COVID-19 pandemic; it is unknown if or when RSV will return to normal seasonality (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37357729']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37357729'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cardiopulmonary bypass patients:</i> IM: Administer a 15 mg/kg dose as soon as possible after cardiopulmonary bypass procedure or at the conclusion of extracorporeal membrane oxygenation, even if &lt;1 month from previous dose. A 58% decrease in palivizumab serum concentrations has been noted after cardiopulmonary bypass (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25070315']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25070315'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51151404"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants and Children &lt;24 months: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51151405"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants and Children &lt;24 months: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F205760"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (27%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Immunologic: Antibody development (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylaxis (very rare; includes angioedema, dyspnea, hypotonia, pruritus, respiratory failure, unresponsiveness, urticaria), hypersensitivity reaction, injection site reaction, thrombocytopenia</p></div>
<div class="block coi drugH1Div" id="F205771"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Significant prior hypersensitivity reaction to palivizumab or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Known hypersensitivity to other humanized monoclonal antibodies.</p></div>
<div class="block war drugH1Div" id="F205757"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid/hypersensitivity reactions: Anaphylaxis and anaphylactic shock, some fatal cases, have been reported following initial exposure or re-exposure to palivizumab; other acute hypersensitivity reactions (may be severe), have also been reported. If a significant hypersensitivity reaction occurs, permanently discontinue therapy. If anaphylaxis or other significant hypersensitivity reaction occurs, administer appropriate medications (eg, epinephrine) and provide supportive care as required. If a mild hypersensitivity reaction occurs, clinical judgment should be used regarding cautious readministration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Palivizumab is not recommended for the prevention of health care-associated RSV disease (AAP 2014). Efficacy has not been established for treatment of RSV disease and use is not recommended (AAP 2014; AAP [Caserta 2023]). A large placebo-controlled trial evaluated 413 infants ≤3 months of age (median age: 49 days) admitted to the hospital through an emergency department with RSV+ bronchiolitis; the treatment group (n=208) received a single dose of palivizumab (15 mg/kg IV); there was no difference between groups in readmission in the 3 weeks following hospital discharge, time to readiness for discharge, or transfer to intensive care during admission (Alansari 2019).</p></div>
<div class="block foc drugH1Div" id="F205766"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synagis: 50 mg/0.5 mL (0.5 mL); 100 mg/mL (1 mL)</p></div>
<div class="block geq drugH1Div" id="F205753"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323593"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Synagis Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/0.5 mL (per 0.5 mL): $2,184.79</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/mL (per mL): $4,125.50</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867822"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synagis: 50 mg/0.5 mL (0.5 mL); 100 mg/mL (1 mL)</p></div>
<div class="block admp drugH1Div" id="F52613509"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IM: Administer undiluted solution IM, preferably in the anterolateral aspect of the thigh; gluteal muscle should not be used routinely as an injection site because of the risk of damage to the sciatic nerve. Injection volume over 1 mL should be given as a divided dose. Do <b>not</b> dilute product; do not shake or vigorously agitate the vial.</p></div>
<div class="block use drugH1Div" id="F205767"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Respiratory syncytial virus prophylaxis:</b> Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients with a history of premature birth (≤35 weeks gestational age) and who are ≤6 months at the beginning of RSV season; pediatric patients with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are ≤24 months at the beginning of RSV season; or pediatric patients with hemodynamically significant congenital heart disease (CHD) and who are ≤24 months at the beginning of RSV season.</p>
<p style="text-indent:0em;margin-top:2em;">The American Academy of Pediatrics (AAP 2014) recommends RSV prophylaxis with palivizumab during RSV season for:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants born at ≤28 weeks 6 days gestational age and &lt;12 months at the start of RSV season</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &lt;12 months of age with chronic lung disease (CLD) of prematurity</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≤12 months of age with hemodynamically significant CHD</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and children &lt;24 months of age with CLD of prematurity necessitating medical therapy (eg, supplemental oxygen, bronchodilator, diuretic, or chronic steroid therapy) within 6 months prior to the beginning of RSV season</p>
<p style="text-indent:-2em;margin-left:2em;">AAP also suggests that palivizumab prophylaxis may be considered in the following circumstances:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &lt;12 months of age with congenital airway abnormality or neuromuscular disorder that decreases the ability to manage airway secretions</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &lt;12 months of age with cystic fibrosis with clinical evidence of CLD and/or nutritional compromise</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;24 months with cystic fibrosis with severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest radiography or chest computed tomography that persist when stable) or weight for length less than the 10th percentile</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and children &lt;24 months who are profoundly immunocompromised</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and children &lt;24 months undergoing cardiac transplantation during RSV season</p>
<p style="text-indent:0em;margin-top:2em;">Limitations of use: Safety and efficacy have not been established for treatment of RSV disease.</p></div>
<div class="block mst drugH1Div" id="F205806"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Synagis may be confused with Synalgos-DC, Synflorix, Synvisc</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299812"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F205762"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F205774"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Not for adult use.</p></div>
<div class="block brc drugH1Div" id="F50297443"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Not for adult use.</p></div>
<div class="block mop drugH1Div" id="F6729951"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Observe for anaphylactic or severe allergic reactions; respiratory syncytial virus infection.</p></div>
<div class="block pha drugH1Div" id="F205756"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Exhibits neutralizing and fusion-inhibitory activity against RSV; these activities inhibit RSV replication in laboratory and clinical studies</p></div>
<div class="block phk drugH1Div" id="F205770"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Infants and Children &lt;24 months without congenital heart disease (CHD): IM: 70%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Infants and Children &lt;24 months without CHD: 20 to 24.5 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: IM: Infants and Children &lt;24 months: 3 to 5 days (Resch 2017); palivizumab concentrations sufficient to inhibit respiratory syncytial virus 2 days after administration (Sáez-Llorens 1998).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance is similar regardless of gestational age, though interpatient variability is high (48.7% coefficient of variation). Clearance may be slightly increased (~20%) in patients with chronic lung disease of prematurity or in the presence of antipalivizumab antibodies (Robbie 2012).</p></div>
<div class="block phksp drugH1Div" id="F54047143"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Trough palivizumab concentrations are similar in pediatric patients with and without congenital heart disease. However, serum concentrations are reduced by an average of 58% following cardiopulmonary bypass (AAP 2014).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F205775"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Synagis</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30760509">
<a name="30760509"></a>Alansari K, Toaimah FH, Almatar DH, El Tatawy LA, Davidson BL, Qusad MIM. Monoclonal antibody treatment of RSV bronchiolitis in young infants: a randomized trial. <i>Pediatrics</i>. 2019;143(3):e20182308.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palivizumab-drug-information/abstract-text/30760509/pubmed" id="30760509" target="_blank">30760509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25070315">
<a name="25070315"></a>American Academy of Pediatrics (AAP). Committee on Infectious Diseases and Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. <i>Pediatrics</i>. 2014;134(2):415-420. doi:10.1542/peds.2014-1665<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palivizumab-drug-information/abstract-text/25070315/pubmed" id="25070315" target="_blank">25070315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2">
<a name="AAP.2"></a>American Academy of Pediatrics (AAP). Updated guidance: use of palivizumab prophylaxis to prevent hospitalization from severe respiratory syncytial virus infection during the 2022-2023 RSV season. Available at https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/interim-guidance-for-use-of-palivizumab-prophylaxis-to-prevent-hospitalization/. Updated November 17, 2022. Accessed November 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11443562">
<a name="11443562"></a>Boeckh M, Berrey MM, Bowden RA, et al, “Phase 1 Evaluation of the Respiratory Syncytial Virus-Specific Monoclonal Antibody Palivizumab in Recipients of Hematopoietic Stem Cell Transplants,” <i>J Infect Dis</i>, 2001, 184(3):350-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palivizumab-drug-information/abstract-text/11443562/pubmed" id="11443562" target="_blank">11443562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37357729">
<a name="37357729"></a>Caserta MT, O'Leary ST, Munoz FM, Ralston SL; Committee on Infectious Diseases. Palivizumab prophylaxis in infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. <i>Pediatrics</i>. 2023;152(1):e2023061803. doi:10.1542/peds.2023-061803<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palivizumab-drug-information/abstract-text/37357729/pubmed" id="37357729" target="_blank">37357729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18043443">
<a name="18043443"></a>Chávez-Bueno S, Mejías A, Merryman RA, et al, "Intravenous Palivizumab and Ribavirin Combination for Respiratory Syncytial Virus Disease in High-Risk Pediatric Patients," <i>Pediatr Infect Dis J</i>, 2007, 26(12):1089-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palivizumab-drug-information/abstract-text/18043443/pubmed" id="18043443" target="_blank">18043443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17879919">
<a name="17879919"></a>de Fontbrune FS, Robin M, Porcher R, et al. Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. <i>Clin Infect Dis</i>. 2007;45(8):1019-1024.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palivizumab-drug-information/abstract-text/17879919/pubmed" id="17879919" target="_blank">17879919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14571236">
<a name="14571236"></a>Feltes TF, Cabalka AK, Meissner HC, et al, “Palivizumab Prophylaxis Reduces Hospitalization Due to Respiratory Syncytial Virus in Young Children With Hemodynamically Significant Congenital Heart Disease,” <i>J Pediatr</i>, 2003, 143(4):532-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palivizumab-drug-information/abstract-text/14571236/pubmed" id="14571236" target="_blank">14571236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18085710">
<a name="18085710"></a>Giebels K, Marcotte JE, Podoba J, et al, "Prophylaxis Against Respiratory Syncytial Virus in Young Children With Cystic Fibrosis," <i>Pediatr Pulmonol</i>, 2008, 43(2):169-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palivizumab-drug-information/abstract-text/18085710/pubmed" id="18085710" target="_blank">18085710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27199622">
<a name="27199622"></a>Helmink BJ, Ragsdale CE, Peterson EJ, Merkel KG. Comparison of intravenous palivizumab and standard of care for treatment of respiratory syncytial virus infection in mechanically ventilated pediatric patients. <i>J Pediatr Pharmacol Ther</i>. 2016;21(2):146-154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palivizumab-drug-information/abstract-text/27199622/pubmed" id="27199622" target="_blank">27199622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9738173">
<a name="9738173"></a>IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. <i>Pediatrics</i>. 1998;102(3, pt 1):531-537.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palivizumab-drug-information/abstract-text/9738173/pubmed" id="9738173" target="_blank">9738173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9359721">
<a name="9359721"></a>Johnson S, Oliver C, Prince GA, et al, “Development of a Humanized Monoclonal Antibody (MEDI-493) With Potent <i>In Vitro</i> and <i>In Vivo</i> Activity Against Respiratory Syncytial Virus,” <i>J Infect Dis</i>, 1997, 176(5):1215-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palivizumab-drug-information/abstract-text/9359721/pubmed" id="9359721" target="_blank">9359721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9815203">
<a name="9815203"></a>Malley R, DeVincenzo J, Ramilo O, et al, "Reduction of Respiratory Syncytial Virus (RSV) in Tracheal Aspirates in Intubated Infants by Use of Humanized Monoclonal Antibody to RSV F Protein," <i>J Infect Dis</i>, 1998, 178(6):1555-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palivizumab-drug-information/abstract-text/9815203/pubmed" id="9815203" target="_blank">9815203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28605249">
<a name="28605249"></a>Resch B. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. <i>Hum Vaccin Immunother</i>. 2017;13(9):2138-2149.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palivizumab-drug-information/abstract-text/28605249/pubmed" id="28605249" target="_blank">28605249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22802243">
<a name="22802243"></a>Robbie GJ, Zhao L, Mondick J, Losonsky G, Roskos LK. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children [published correction appears in <i>Antimicrob Agents Chemother</i>. 2012;56(10):5431]. <i>Antimicrob Agents Chemother</i>. 2012;56(9):4927-4936.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palivizumab-drug-information/abstract-text/22802243/pubmed" id="22802243" target="_blank">22802243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9779762">
<a name="9779762"></a>Sáez-Llorens X, Castaño E, Null D, et al. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group. <i>Pediatr Infect Dis J</i>. 1998;17(9):787-791.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palivizumab-drug-information/abstract-text/9779762/pubmed" id="9779762" target="_blank">9779762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15295219">
<a name="15295219"></a>Sáez-Llorens X, Moreno MT, Ramilo O, et al, "Safety and Pharmacokinetics of Palivizumab Therapy in Children Hospitalized With Respiratory Syncytial Virus Infection," <i>Pediatr Infect Dis J</i>, 2004, 23(8):707-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palivizumab-drug-information/abstract-text/15295219/pubmed" id="15295219" target="_blank">15295219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9493805">
<a name="9493805"></a>Subramanian KN, Weisman, LE, Rhodes T, et al, “Safety, Tolerance and Pharmacokinetics of a Humanized Monoclonal Antibody to Respiratory Syncytial Virus in Premature Infants With Bronchopulmonary Dysplasia. MEDI-493 Study Group,” <i>Pediatr Infect Dis J</i>, 1998, 17(2):110-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/palivizumab-drug-information/abstract-text/9493805/pubmed" id="9493805" target="_blank">9493805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Synagis.1">
<a name="Synagis.1"></a>Synagis (palivizumab) [prescribing information]. Waltham, MA: Sobi Inc; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Synagis.2">
<a name="Synagis.2"></a>Synagis (palivizumab) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; July 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9849 Version 164.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
